CCDC82 Knockout NCI-H1299 Polyclonal Cells are a polyclonal knockout cell population generated through CRISPR/Cas9-mediated disruption of the CCDC82 gene in the NCI-H1299 human lung adenocarcinoma epithelial cell line. This product is provided as a heterogeneous pool of edited cells, offering a cost-effective and rapid model for loss-of-function studies without the need for single-cell clone isolation. The polyclonal format preserves genetic diversity while ensuring robust target-gene inactivation across the population, making it suitable for bulk assays in cancer cell biology.
NCI-H1299 is a widely used non-small cell lung cancer (NSCLC) model derived from the metastatic lymph node of a lung adenocarcinoma patient. These epithelial cells retain key characteristics of lung adenocarcinoma, including a homozygous partial deletion of the TP53 gene, and are highly tumorigenic in immunocompromised mice. The NCI-H1299 background provides a clinically relevant platform for investigating genes involved in NSCLC progression, metastasis, and therapeutic resistance.
CCDC82 encodes a coiled-coil domain-containing protein with a predicted role in cytoskeletal organization and microtubule dynamics. Although its upstream regulators and downstream targets remain uncharacterized, CCDC82 is thought to function within microtubule-based processes and cytoskeleton remodeling pathways, potentially interacting with tubulin, actin filaments, and centrosomal components. Mechanistically, CCDC82 may mediate intracellular trafficking and cell architecture, and its disruption in the NCI-H1299 line offers a model to study how loss of this protein affects microtubule stability, cell adhesion, and proliferation.
In lung adenocarcinoma cells, the polyclonal CCDC82 knockout enables dissection of the gene’s contribution to cancer cell behaviors such as migration, invasion, and cytoskeletal remodeling. Because CCDC82 has no established disease associations, this model is particularly valuable for exploratory studies seeking to uncover novel functions in NSCLC. Disruption of CCDC82 may lead to altered microtubule dynamics, impacting cell morphology and metastatic potential, thus providing a tool to interrogate the role of microtubule-associated proteins in tumor progression.
Key applications include Western blotting and RT-qPCR for knockout validation, immunofluorescence staining of microtubule and actin networks to visualize cytoskeletal changes, and cell proliferation assays (MTT or BrdU) to assess growth defects. Migration and invasion can be evaluated using Transwell assays, while flow cytometry enables cell cycle and apoptosis analysis. Furthermore, this polyclonal knockout cell population is well-suited for synthetic lethal screening and drug sensitivity testing in the context of lung adenocarcinoma. For additional information or custom services, please contact Ascent Research.
